• If you are wondering whether Corteva's current share price really reflects its long term potential, this article walks through the key numbers that matter for value focused investors.
• Corteva's share price recently closed at US$78.30, with returns of 7.9% over the last 30 days and 31.3% over the past year, even though the last 7 days saw a 2.8% decline.
• Recent coverage around Corteva has centered on its position in the agricultural inputs space and how investors are weighing its role in global food production against changing market expectations. This context helps explain why the stock has seen both short term pullbacks and longer term gains as sentiment shifts.
• Corteva currently records a valuation score of 1 out of 6. Next we will look at how different valuation methods assess the stock, followed by a more holistic way to think about value that goes beyond a single score.

Corteva scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corteva Discounted Cash Flow (DCF) Analysis

A DCF model takes estimates of the cash a business could generate in the future, then discounts those cash flows back to today to arrive at an estimated intrinsic value per share.

For Corteva, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about US$2.8b. Analysts provide explicit Free Cash Flow estimates out to 2029, with Simply Wall St extending this path further using its own assumptions. The ten year projection set includes a 2029 Free Cash Flow input of roughly US$2.6b, with later years extrapolated rather than directly forecast by analysts.

Bringing these projected cash flows back to today using the DCF framework gives an estimated intrinsic value of US$80.09 per share. Compared with the recent share price of US$78.30, the model implies Corteva trades at a 2.2% discount, which is a very small gap and within a normal margin of error for this type of analysis.

Result: ABOUT RIGHT

Corteva is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Corteva.

Approach 2: Corteva Price vs Earnings

For a profitable business like Corteva, the P/E ratio is a useful way to gauge what investors are currently willing to pay for each dollar of earnings. It links directly to profitability, which is usually the core driver of long term equity value.

What counts as a “normal” P/E often reflects how the market views a company’s growth prospects and risk profile. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher risk tends to line up with a lower one.

Corteva currently trades on a P/E of 44.14x. That sits above the Chemicals industry average of 25.57x and also above the peer average of 20.22x, so on simple comparisons the stock carries a richer valuation.

Simply Wall St’s Fair Ratio is designed to go a step further. It estimates what P/E might make sense for Corteva given factors such as earnings growth, profit margins, industry, market cap and company specific risks, instead of just lining it up against peers. For Corteva, this Fair Ratio is 27.24x, which is below the current 44.14x, indicating the shares look overvalued on this framework.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Corteva Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, where you spell out your story for Corteva in plain language, tie that story to your own revenue, earnings and margin estimates, and see a fair value that updates automatically as new news or earnings arrive. This helps you compare that fair value with today’s price when you are thinking about buying or selling. For example, one Corteva Narrative might lean into strong demand for resilient seeds, biologicals and gene editing, cost optimization and higher margins to arrive at a fair value close to US$92. Another might stress competition, currency swings, regulatory pressure and weaker pricing power to support a more cautious view closer to US$68. Both perspectives sit side by side on the platform so you can quickly see how different assumptions translate into very different numbers.

Do you think there's more to the story for Corteva? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.